The secondary active cation–chloride cotransporters (CCCs) utilize the existing Na+ and/or K+ gradients to move Cl− into or out of cells. NKCC1 is an intensively studied member of the CCC family and plays fundamental roles in regulating trans-epithelial ion movement, cell volume, chloride homeostasis and neuronal excitability. Here, we report a cryo-EM structure of human NKCC1 captured in a partially loaded, inward-open state. NKCC1 assembles into a dimer, with the first ten transmembrane (TM) helices harboring the transport core and TM11-TM12 helices lining the dimer interface. TM1 and TM6 helices break α-helical geometry halfway across the lipid bilayer where ion binding sites are organized around these discontinuous regions. NKCC1 may harbor multiple extracellular entryways and intracellular exits, raising the possibility that K+, Na+, and Cl− ions may traverse along their own routes for translocation. NKCC1 structure provides a blueprint for further probing structure–function relationships of NKCC1 and other CCCs.
Cation–chloride cotransporters (CCCs) are secondary active symporters that harness the K+ and/or Na+ gradients generated by the Na+-K+-ATPase to extrude or uptake Cl− in various cell types1,2,3,4,5. CCCs consist of two branches: three Na+-dependent Na+-(K+)-Cl− (NCC and NKCC1-2) and four Na+-independent K+-Cl− (KCC1–4) cotransporters. NKCC1 is one of the most extensively studied members of the CCC family and plays pivotal roles in trans-epithelial ion absorption and secretion, cell volume regulation, and regulation of chloride homeostasis and neuronal excitability, among others6. In most cell types, NKCC1 regulates cell volume in response to hypertonic stress as NKCC1-mediated Cl− uptake and concomitant obligatory water influx represent a major defense mechanism against cell shrinkage. In polarized secretory epithelia cells, NKCC1 is highly expressed in the basolateral membrane where it absorbs Cl− that is then secreted via other apically localized transport proteins (e.g., CFTR). In periphery sensory neurons and postnatal immature neurons, NKCC1 activity contributes to maintaining elevated [Cl−]i such that GABA (γ-aminobutyric acid), a principle inhibitory neurotransmitter, stimulates Cl− efflux and therefore, produces depolarizing and excitatory inward currents in these neurons. Given its role as a principle neuronal Cl− accumulator that affects polarity of GABA responses, NKCC1 is an emerging target for developing therapeutics to treat neonatal seizures, neuropathic pain, and other neurological disorders7,8,9,10,11,12.
In the kidneys, NKCC2 and NCC are primary transport proteins involved in salt reabsorption in the apical membrane of the thick ascending limb of Henle’s loop and distal convoluted tubule of nephrons, respectively. Loss-of-function mutations of NKCC2 and NCC, respectively, lead to Bartter type I and Gitelman syndrome characterized by salt wasting and decreased blood pressure due to attenuated salt reabsorption13,14,15. Conversely, abnormally enhanced activity of NCC has been linked to salt-sensitive hypertensive disorders such as Gordon disease16,17,18. Given their fundamental roles in regulating blood volume and pressure, NKCC2 and NCC are attractive targets for developing novel anti-hypertensive therapeutics. Indeed, the loop and thiazide-type diuretics directly inhibit NKCC2 and NCC, respectively, and have been widely prescribed to treat hypertension and edema19,20.
CCCs belong to the large amino acid-polyamine-organocation (APC) superfamily of transporters. Structures of several APC transporters demonstrate that they all exhibit a rough twofold symmetry such that two inverted repeats of five transmembrane (TM) helices together form a central substrate binding cavity21,22. This pseudo-symmetric topology of two inverted repeats is the linchpin of the alternating-access mechanism whereby transporters isomerize among outward-open, occluded, and inward-open states to translocate substrates across membranes23. Hydropathy plot analyses and structure modeling based on related APC transporter structures predict that all CCCs share a common structural architecture with twelve TM helices harboring a 5 + 5 inverted repeat fold flanked by cytoplasmic N- and C-terminal domains1,24,25. CCCs are homo- or hetero-dimers and their C-terminal domains contribute to dimer assembly26,27,28,29,30. Despite a rudimentary functional map emerged from numerous mutagenesis studies of CCCs, essential structural features that underlie substrate binding and translocation, oligomeric assembly, inhibition by diuretics, and allosteric regulation by phosphorylation remain lacking.
Here, we report a cryo-EM structure of human NKCC1 captured in a partially loaded, inward-open state. NKCC1 assembles into a dimer partly via an interface formed by TM11–TM12 helices within the membrane bilayer. TM1 and TM6 helices lie at the core of the transport pathway with broken α-helical geometry roughly halfway across the lipid bilayer where two strictly conserved glycine residues may serve as flexible hinges that could facilitate the transporter to isomerize among different functional states. Ion binding sites are organized around these hinge regions with partially charged side chains, main chain atoms, and helix dipoles playing crucial roles in coordinating ions. In contrast to LeuT and many other APC transporters, NKCC1 seems to harbor multiple extracellular entryways and intracellular exits that converge at central ion binding sites, raising the possibility that K+, Na+, and Cl− ions may traverse along their own routes for translocation. Our human NKCC1 structure provides a blueprint for further probing structure–function relationships of NKCC1 and other CCCs.
We identified a human NKCC1 construct that eluted as a monodisperse peak on a size exclusion column and yielded homogenous particles suitable for 3D reconstruction by single-particle cryo-EM (Supplementary Fig. 1A). This construct bears deletions in two regions (255–278 within the cytoplasmic N-terminus; 941–1000 within the cytoplasmic C-terminal domain) that are divergent among Na+-dependent CCCs, as well as two single mutations (K289N and G351R). K289N mutation was found to enhance protein expression and G351R is a loss-of-function variant that was cloned from MDCK-LK-A3 cell line rendered deficient in co-transporting Na+–K+–2Cl− ions by random mutagenization31. We performed Tl+ ion flux assay and found that NKCC1 bearing K289N mutation showed bumetanide (an inhibitory loop diuretic)-sensitive transport activity comparable to the wild-type NKCC1, and additional inclusion of the two above mentioned deletions resulted in a transporter with no statistically significant transport activity. As expected, our cryo-EM construct that further bears the G351R loss-of-function mutation showed complete loss of transport function, as compared with the wild-type NKCC1 (Supplementary Fig. 1B-E). We speculated that this NKCC1 construct may be arrested in a specific state along the transport cycle, and thus could be more conformationally homogeneous for structural analyses. NKCC1 transport activity is enhanced by phosphorylation at several conserved Ser/Thr residues at its N-terminus likely due to increased structural dynamics of its large cytoplasmic C-terminal domains30,32,33,34,35. To further minimize structural flexibility, we co-expressed the NKCC1 construct with phosphatase PP1α and treated purified transporter protein with recombinant PP1α to promote a fully de-phosphorylated (inactive) transport state36. We also excluded K+ ion, a substrate that NKCC1 translocates, during sample preparation, which we speculated may prevent NKCC1 from completing a full transport cycle and further arrest the transporter in a specific state. We determined human NKCC1 transporter structure at 3.46 Å resolution that allows for de novo model building (Fig. 1; Supplementary Figs. 2, 3, and 4). The final map shows well-resolved densities for the transmembrane domain, large extracellular domains, and loops connecting membrane-spanning helices; however, it lacks interpretable densities for the cytosolic domains, consistent with reference free 2D class averages that show merely a cloud of fuzz densities for the cytosolic domains (Supplementary Fig. 2). A recently reported Danio rerio NKCC1 structure successfully resolved the cytoplasmic C-terminal domains37, whereas the human KCC1 structures also failed to resolve the C-terminal domains38.
Dimeric architecture of the human NKCC1 transporter
As expected from previous biochemical crosslinking, FRET (fluorescence resonance energy transfer), and structural analyses26,27,28,29,30,37, NKCC1 assembles as a homodimer, exhibiting twofold symmetry along an axis perpendicular to the membrane (Fig. 1a, b). Overall, our human NKCC1 structure largely superimposes with that of Danio rerio NKCC1, with major differences residing at their extracellular domains and loops collecting transmembrane helices (Supplementary Fig. 5A). Of note, human NKCC1 and KCC1 adopt a drastically different dimeric architecture, although a single subunit of these transporters superimposes nicely within the transmembrane region (Supplementary Fig. 5B). Each NKCC1 monomer consists of twelve membrane-spanning helices with the first five helices (TM1–TM5) related to the next five helices (TM6–10) by a pseudo twofold symmetry axis parallel to the membrane. The remaining TM11–TM12 helices adopt an inverted V-shaped helix-turn-helix structure and associate with the same structure from a second subunit, constituting the primary dimerization interface within the lipid bilayer in addition to that formed by the cytoplasmic C-terminal domains (Fig. 1b). Notably, in contrast to significant conservation (~64% identical) within their TM1–TM10 helices, NKCC1, NKCC2, and NCC exhibit only modest sequence identity (~38%) within their TM11–TM12 helices, providing a plausible explanation for lack of heteromeric dimers among these transporters (Supplementary Fig. 6). Mismatches within the dimeric interface of their cytoplasmic C-terminal domains may represent another mechanism that heteromeric dimers are disfavored within the Na+-dependent clade of CCCs27. On the contrary, four KCC (KCC1–4) transporters bear almost identical sequences in their TM11–TM12 helices and thus are expected to form complementary dimer interfaces within the lipid bilayer. Indeed, KCC isoforms assemble into various heteromeric transporters when co-expressed in heterologous host cells28. Beside these major transmembrane helices, an extracellular loop (EL)-4 helix preceding TM8 and an intracellular loop (IL)-1 helix between TM2 and TM3 lie almost parallel to and are in close contact with the outer and inner leaflets of the bilayer, respectively (Fig. 1c). These two short helices are related by the internal pseudo symmetry and seem to be strategically positioned to affect the extracellular and intracellular gates, respectively.
Interestingly, the NKCC1 transmembrane core adopts a conspicuously curved architecture because TM helices located at the periphery of the dimer are gradually elevated toward the extracellular side as compared with those residing at the center of the dimer (Fig. 1a, b). Indeed, the most periphery helices (TM4–TM5) are situated ~9 Å above the central helices (TM11–TM12). This curved dimer raises the possibility that the lipid bilayer might be deformed at regions where NKCC1 transporter density (and activity) is substantial (e.g., basolateral membrane of secretory epithelia) and that membrane fluidity could regulate NKCC1 transport activity.
Above the transmembrane core of NKCC1, two large extracellular loops (EL3 between TM5 and TM6; EL4 between TM7 and TM8) fold into ordered structures that sit atop and interact extensively with the transmembrane core (Fig. 2a). Of note, EL4 is stabilized by two disulfide bonds (Cys563–Cys568 and Cys577–Cys582; Fig. 2a), consistent with a previous finding that these four cysteine residues do not react with reagents that modify free -SH group39. Notably, substitution of C421 in NCC (equivalent to Cys568 in human NKCC1) to Arg causes Giltelman’s disease in human possibly by disrupting this essential stabilizing disulfide bridge40. Interestingly, in the Danio rerio NKCC1 structure, only a single disulfide bond equivalent to Cys577–Cys582 in human NKCC1 was observed; the other pair of cysteines (equivalent to Cys563 and Cys568 in human NKCC1) are in close proximity, but appear not to form a covalent bond37. This subtle difference likely reflects the fact that the EL4 loop is one of the most divergent segments among various NKCC1 homologs.
One particular interesting interaction network involves the extracellular end of TM1, a C-terminal segment of EL3 preceding TM6, and an EL4 segment immediately following TM7 (Fig. 2b). Here, Arg546 residing at EL4 makes extensive hydrophilic contacts with main chain carbonyl oxygens from residues Gly313, Gln314, Glu475, and Gly478, as well as side chains of Asn476 and Asp480. In addition, Arg546 possibly also neutralizes the negative dipole existing at the C-termini of TM1 helix. Importantly, this arginine residue is invariant in all CCCs and mutation of this Arg to Cys in NCC (R399C) results in Giltelman’s syndrome, highlighting the importance of this interaction network in supporting transport function40. Although EL3 and EL4 of NKCC1, NKCC2, and NCC share several highly conserved motifs, these extracellular structures are by far more divergent in primary sequences than transmembrane helices. Future studies will determine whether this sequence diversity can be exploited to target these functionally important extracellular structures for developing isoform-specific pharmacological agents to treat various human diseases.
Ion transport pathways
From a bird’s eye view, NKCC1 shares many structural hallmarks in its substrates (i.e., ions) transport pathway with other APC transporters, such as LeuT that mediates Na+-coupled leucine uptake in Aquifex aeolicus41, in line with previous modeling and mutagenesis studies24. LeuT arguably represents the best understood APC transporter with respect to its transport mechanisms due in no small part to insights gained by a series of LeuT structures captured in outward-open, occluded, or inward-open states42,43. We therefore superimposed TM1–TM10 helices of our human NKCC1 structure onto each of these LeuT structures and found that NKCC1 structure aligns best with that of the occluded state of LeuT (Fig. 3a, b); TM11 and TM12 helices were excluded in these comparisons because they are two optional helices in APC transporters and, when present, tend to have diverse structural and functional roles in different transporters44. There was one important caveat in such comparisons because NKCC1 transports K+, Cl−, and Na+ ions, all of which are significantly smaller in size than LeuT substrate leucine. We therefore mapped potential membrane-embedded solvent accessible channels using program HOLE45. We found that three potential extracellular entryways (I, II, and III) lead to central ion binding sites and that three putative intracellular conduits (IV, V, and VI) would allow ions to exit central sites into cytoplasm (Fig. 3c). These ion pathways are primarily formed by TM1, TM2, TM3, TM6, TM8, and TM10 helices that are rich in partially charged hydrophilic residues (e.g., Ser, Thr, Asn, and Tyr), but lack formal charged residues (e.g., Glu and Asp). Such arrangement likely reflects a functional requirement because Glu and Asp residues tend to interact strongly with ions and thus could impede ion transport. Indeed, merely replacing Glu290 to Ser in LeuT establishes a new Cl− binding site along the translocation pathway and converts LeuT into a Na+/Cl− dependent transporter46,47. All three extracellular entryways are constricted, with the shortest distances between opposing side chains being 3.3 Å in entryway I, 4.3 Å in entryway II, and 4.9 Å in entryway III, and appear to be impermeable to hydrated K+ (6.0 Å), Cl− (5.8 Å), or Na+ (6.6 Å) ions (Fig. 3c). In contrast, all three intracellular pathways are considerably wider than entryways and comparable to ion permeation pathways seen in open ion channels. In particular, the pathway IV, a vestibule formed by TM1, TM6, TM5, and TM8, is sufficiently wide for unobstructed flow of fully hydrated ions once they dissociate from their ruptured central binding sites. Of note, this widest intracellular pathway is topological equivalent to an intracellular vestibule observed in an inward-open LeuT through which leucine exits central substrate binding site43. We therefore concluded that our NKCC1 structure is likely trapped in an inward-open state.
Central ion binding sites
As first discovered in LeuT42, TM1 and TM6 helices of NKCC1 also become discontinuous roughly at the middle of the membrane bilayer and are separated into four half helices, with two glycine residues residing at the hinge regions (Gly301 between TM1a and TM1b; Gly500 between TM6a and TM6b; Fig. 3b). These two glycine residues are strictly conserved in all CCCs and may function as two flexing points around which four half helices can bend to facilitate isomerization of transporters among different states, as observed in LeuT43. Indeed, a loss-of-function G193R variant of NKCC2 (equivalent to Gly301 in human NKCC1) results in Bartter’s disease, highlighting the functional importance of bearing a flexible glycine in this hinge region48. Similar to LeuT, ion binding sites in NKCC1 are also organized around these two hinge regions, with nearby hydrophilic side chains, main chain atoms, and helix dipoles playing key roles in ion coordination (Fig. 4)42.
We intentionally excluded K+ from our sample in order to arrest NKCC1 in a specific transport state and accordingly did not observe K+ density in our map. A recent Danio rerio NKCC1 structure was determined using a sample containing K+ ion and resolved K+ binding site37. Much to our surprise, human and Danio rerio NKCC1 structures essentially superimpose at the K+ binding site, indicating that lack of K+ coordination alone does not lead to rupture of the K+ binding site possibly because it is structurally coupled to and stabilized by nearby Na+ and Cl− binding sites. A similar finding was recently discovered in human KCC1 where exclusion of K+ also does not appreciably perturb the structure of the transporter38. In human NKCC1, the K+ ion binding site comprises of exclusively partial charges, including main chain carbonyl oxygen atoms of Asn298 (TM1), Ile299 (TM1), Thr499 (TM6), and Pro496 (TM6), as well as hydroxy groups of Tyr383 (TM3) and Thr499 (Fig. 4c). Tyr383 plays a crucial role in ion transport possibly by defining K+ specificity, as even a conserved substitution of this Tyr to Phe renders human NKCC1 inactive49. Of note, the NCC transporter conspicuously bears a histidine (H234) at this position (Supplementary Fig. 6), providing a plausible explanation for its K+-independent cotransport of only Na+ and Cl− ions as noted previously37. Intriguingly, all the four remaining K+ coordination residues are strictly conserved in NCC, making us wonder whether substitution of this Tyr to His could transform a K+ binding site in NKCC1, NKCC2, and KCCs into perhaps a Cl− binding site. Indeed, the N–H on histidine imidazol group frequently serves as a hydrogen bond donor in coordinating Cl− ion in other Cl− binding proteins50. Irrespective of whether this histidine and other four residues participate in Cl− binding in NCC, they are certainly crucial for NCC function as mutations in two of these residues (H234Q and P349L) are associated with Giltelman’s disease40.
Our human NKCC1 map lacks non-protein densities that could be ascribed to Na+ ion as does the recently reported Danio rerio NKCC1 structure37. However, NKCC1 exhibits remarkable conservation with LeuT at a Na+ binding site commonly referred to as Na+ site 2 in APC transporters and bears all the structural and chemical hallmarks essential for Na+ coordination42. In human NKCC1, this putative Na+ binding site consists of residues residing on TM1 and TM8 helices, including Leu297 and Trp300 on TM1 and Ala610, Ser613, and Ser614 on TM8 (Fig. 4d). Similar to the K+ binding site, the Na+ binding site involves main chain oxygen atoms and hydroxyl groups of two serine residues, without contribution from any formal charged residues. Remarkably, these five residues are invariant in NKCC1, NKCC2, and NCC, likely reflecting a stringent functional requirement for all Na+-dependent CCCs. Indeed, perturbations of this putative Na+ binding site by genetic mutations lead to human diseases, including an NCC A467T variant associated with the Giltelman’s disease and an NKCC2 S507P variant found in Bartter’s disease patients40,48. The putative NKCC1 Na+ binding site also aligns with the Na+ site 2 in the SiaT transporter as previously noted37, further corroborating that these five residues constitute a Na+ binding site in NKCC1 and perhaps in NKCC2 and NCC as well. Of note, the recently reported human KCC1 structures lack this putative Na+ binding site, lending further evidence to support the presence of Na+ in this site38.
The extracellular gates and entryways
Our human NKCC1 structure showed closed extracellular gates as all three potential solvent accessible entryways leading to central ion binding sites are too constricted to permit hydrated K+, Na+, and Cl− ions to flow through. TM1b, TM6a, extracellular ends of TM3 and TM10, and a short EL4 helix preceding TM8 are in close proximity and together form impermeable barriers for hydrated ions just beneath the outer leaflet of the membrane bilayer (Fig. 5a, b). These barriers (or gates) are likely stabilized by a multitude of hydrophobic, hydrogen bonding, and ionic bonding interactions that involve a set of conserved residues. One most extensive interaction hub involves Arg307 and Trp310 on TM1a, Glu389 on TM3, Phe590 on an EL4 helix, and Asn672 on TM10, offering an immediate impression that these hydrophilic interactions may staple these structural elements together and hence force closure of the extracellular gates (Fig. 5c). In particular, Arg307 appears to play a central role in coordinating this interaction hub as it interacts with Glu389, Asn672, and Phe590 via salt bridge, hydrogen bond, and cation-π, respectively. Several clinical mutations likely affect the overall structure and/or conformational dynamics of the extracellular gates, including two NCC variants (R158Q and R158L) found in patients with Giltelman’s disease and three NKCC2 variants (R199C, R199G, and W202C) associated with Bartter’s syndrome40,48. The fact that substitutions of this arginine to four amino acids of different sizes and chemical properties in NCC and NKCC2 are all pathogenic underscores a potentially conserved role for this arginine residue in closing extracellular gates that represents an essential step along a transport cycle for any solute carrier transporters. This arginine residue is also conserved in all KCCs, suggesting that similar gating interactions may operate in these transporters as well. Even more remarkably, in LeuT, an equivalent arginine residue interacts with an aspartate residue via a salt bridge, which contributes to closing an extracellular gate to allow the transporter to isomerize into an inward-open state43.
The intracellular pathways and opened intracellular gates
Our human NKCC1 structure showed three intracellular vestibules (IV, V, and VI) that converge at a central cavity located halfway across membrane where three ions bind to their respective sites. All of these three intracellular pathways are notably wider than the three entryways and would afford unobstructed conduits for ions to reach cytoplasm once they dissociate from their central binding sites. The three intracellular vestibules are lined by a multitude of hydrophilic residues which may be essential for maintaining these pathways in a hydrated state for efficient ion translocation (Fig. 6a). This has been previously shown in ion channels that a hydrophobic pore with a diameter <14 Å can spontaneously de-wet (or lose water) and prevent ion conduction51. For instance, the intracellular vestibule V is primarily formed by TM2 and a short helix on intracellular loop 1 (IL1), with three hydrophilic residues (Thr334, Thr338, and Ser359) pointing their hydroxy groups toward the center of the ion pathway (Fig. 6a). Interestingly, human NKCC2 has three splicing isoforms (A, B, and F) that differ only in TM2 and IL1, yet exhibit different affinities for ions52,53. Although conversions of many isoform-specific residues within this region, including two hydrophobic residues, accordingly convert ion affinity profiles, Thr249 (equivalent to Thr338 in NKCC1) appears to have the largest effect on Cl− affinity54,55. Moreover, in NKCC1, substitution of Asn376, which resides just beneath central ion binding sites, to cysteine reduces affinity to all three ions, whereas N376W mutant completely loses transport function possibly because the bulky tryptophan may plug the ion pathway49.
Our human NKCC1 structure is trapped in an inward-open state, so residues and interactions that would close intracellular gates in outward-open or occluded states await future structural and functional analyses. Here, we focus on understanding how intracellular gates are stabilized in an open configuration in the inward-open state. The entryway of the widest intracellular vestibule (or pathway IV) is surrounded by TM1a, TM6b, TM5, and TM8 (Fig. 6b), among which TM1a and TM6b may be the most mobile structural elements as they could undergo hinge-bending movements around two hinges located halfway across the lipid bilayer as seen in LeuT43. A stable open intracellular gate conceivably involves formation of new gating interactions that would immobilize TM1a and TM6b. Indeed, in our NKCC1 structure, TM1a is anchored to TM5 by hydrogen bonding interactions between Arg294 (TM1a) and Gln435 (TM5). R294A mutation resulted in reduced transport activity as measured by Tl+ ion flux assay when compared with the wild-type NKCC1 (Fig. 6c, d). In addition, substitution of R145 (equivalent to Arg294 in human NKCC1) to cysteine in NCC results in Giltelman’s disease40. Together, these observations suggested a key gating role for this conserved arginine in Na+-dependent CCCs. TM6b also appears to be constrained as the cytoplasmic end of TM6b and the intracellular loop (IL3) immediately following it are in close contact with IL1 (349GGGA352) via hydrogen bonding interactions. We used a loss-of-function G351R variant of NKCC1 for structure determination and interestingly31, this arginine residue establishes additional hydrogen bonding interactions with TM6a and IL3 (Fig. 6b). Notably, a similar mutation (G243D) in NKCC2 causes mild Bartter’s disease54 and it remains to be determined whether this aspartate can also engage in hydrogen bonding interactions as does arginine in the NKCC1 G351R variant.
NKCC1 shares similar structural design principles with LeuT and many other APC transporters, including TM1 and TM6 helices being discontinuous at the middle of the lipid bilayer and substrate binding sites centered around these discontinuous hinge regions. However, NKCC1 unusually has multiple extracellular entryways and intracellular exits that converge at central ion binding sites located approximately halfway across the membrane bilayer. Such design of multiple translocation pathways could simply reflect that ions shuttled by NKCC1 are much smaller in size than leucine and other bulky substrates translocated by other APC transporters, so these pathways could just be redundant. A more provocative explanation, though, is that Na+, K+, and Cl− ions need traverse along separate routes to cross the membrane bilayer. Of note, three negatively charged residues, Glu429 and Glu431 located on TM5 and Asp510 located on IL3, surround the intracellular opening of the vestibule IV, offering an impression that such electronegativity would attract and facilitate conduction of K+ and Na+, but not Cl−, as first seen in KcsA and later in many other cation channels as well56. Another important structural trait of NKCC1 is that it may undergo more subtle conformational changes than other APC transporters as these transporters proceed along the transport cycle. Indeed, our NKCC1 structure is captured in an inward-open state, but aligns best with the occluded structure of LeuT, as intracellular vestibules that are sufficiently wide for ions to reach central binding sites in NKCC1 would block bulky substrates such as leucine. Subtle conformational changes required for alternating among different functional states in NKCC1 may also explain why it exhibits much faster turnover rate (~3500/s at 37 °C) than other APC transporters as previously noted49.
Human and Danio rerio NKCC1 structures were determined in buffer containing two substrate ions Na+ and Cl− or all three substrate ions, respectively, so they are expected to be captured in two distinct substrate bound states, yet these two structures essentially superimpose and are all trapped in an inward-open conformation. In a recent kinetic transport model of NKCC157, inward-open transporter first binds a Cl−, then a Na+, followed by a second Cl− and a K+. This model further proposes that binding of Na+ and Cl−, or of K+ and Cl− are strictly coupled, so eletroneutral ion transport is guaranteed. This model also allows incomplete transport reaction to occur whereby a partially loaded transporter (e.g., loaded only with Na+ and Cl−) changes conformation and opens to the opposite site of membrane, resulting in for example K+/K+ exchange, instead of unidirectional transport of Na+–K+–2Cl−. Using this kinetic model as a reference, our human NKCC1 structure would represent an inward-open transporter partially loaded with a Na+ and a Cl− and arrested on route before binding K+ and Cl− because K+ was excluded in sample preparation, whereas the Danio rerio NKCC1 structure represents an inward-open transporter fully loaded with K+, Na+, and Cl− ions. We showed that the partially loaded, inward-open NKCC1 transporter is thermodynamically stable and surprisingly resembles a fully loaded transporter in structure. It is conceivable that this partially loaded NKCC1 transporter could isomerize into outward-open conformation and if true, then can account for experimental observations that NKCC1 can function partially to mediate K+/K+ exchange in several cell types and physiological conditions12,58,59. Our human NKCC1 structure, together with zebrafish NKCC1 and human KCC1 structures37,38, now provides a blueprint for further probing structure–function relationships of NKCC1 and other CCCs.
Primers for cloning all expression constructs of human NKCC1 used in this study are listed in Supplementary Table 1.
Expression and purification of human NKCC1
The human NKCC1 construct, encompassing residues 2–1212 and bearing deletions in two regions (255–278 within the cytoplasmic N-terminus; 941–1000 within the cytoplasmic C-terminal domain) and two single mutations (K289N and G351R), was expressed with an N-terminal maltose binding protein (MBP) fusion in HEK293S GnTI− (ATCC CRL-3022) cells using the BacMam system as described60. Human PP1α (2–330) also with an N-terminal MBP fusion was co-expressed with NKCC1 to de-phosphorylate transporters within cells. In brief, HEK293S GnTI−/− cells, grown in suspension in freestyle 293 expression medium (Invitrogen, Carlsbad, CA) at 37 °C in an orbital shaker, were transduced with NKCC1 and PP1α baculoviruses when cell density reached ~2 × 106/ml. Eight to twenty-four hours post transduction, sodium butyrate was added to the culture to a final concentration of 5 mM to enhance protein expression; temperature was reduced to 30 °C. Cells were harvested 72 h post transduction for subsequent affinity purification with amylose resin (New England BioLabs, Ipswich, MA). Human NKCC1 protein was eluted from amylose resin with buffer composed of (in mM) 50 HEPES (pH 7.4), 150 NaCl, 0.5 TCEP, 0.5 MNG-3, 0.1 CHS, 1 MnCl2, 20 maltose, 0.1 mg/ml soybean lipids, 10% glycerol. Recombinant PP1α was then added to purified NKCC1 proteins for further de-phosphorylation overnight and MBP tag was simultaneously removed by protease cleavage. NKCC1 transporter was separated with a Superose 6 column using buffer composed of (in mM) 20 HEPES (pH 7.4), 150 NaCl, 0.5 TCEP, 25 × 10−3 MNG-3, and 5 × 10−3 CHS, and peaks corresponding to NKCC1 were pooled and concentrated for cryo-EM analyses.
Thallium ion (Tl+) flux transport assay
The NKCC1-mediated K+ flux was measured using Tl+ as a surrogate ion according to previously published protocols with slight modifications61. Briefly, the wild-type human NKCC1 and three mutants were expressed in HEK293T cells (ATCC CRL-3216) as an N-terminal YFP fusion proteins using BacMam expression system that typically reached peak YFP fluorescence in 48 h post transduction. Expression of R294A and wild-type NKCC1 was also confirmed by western blot using mouse anti-GFP antibody (Roche, Cat. No. 11,814,460,001; 1:1000 dilution). For transport assay, ~1.25 × 105 HEK293T cells were seeded per well in a 96-well plate 1 day prior to baculovirus transduction, and sodium butyrate was added to each well at 5 mM final concentration 8–12 h post transduction to boost transporter expression. Transport assay was performed between 36 and 60 h post transduction. Growth DMEM media was replaced with 80 µL of low Cl− buffer (15 mM Na-HEPES, pH 7.4, 135 mM Na-gluconate, 1 mM MgCl2–6H2O, 1 mM Na2SO4, 1 mM CaCl2–2H2O) supplemented with FluxOR™ Red dye, power load reagent and probenecid provided in the FluxOR-Red Potassium Ion Channel Assay kit (Thermo Fisher Scientific), and cells were incubated at 37 °C for 1 h. Dye-loaded cells were then washed with the same low Cl− buffer mentioned above or washed with low Cl− buffer supplemented with 33 µM bumetanide. Fluorescence intensity was measured on a Synergy Neo2 HTS Multi-Mode Microplate Reader (BioTek) using bottom read mode with 4.5 mm read height. Excitation wavelength (540 nm) and emission wavelength (590 nm) were controlled by monochromator. The transport assay was initiated by adding 20 μl of 12 mM thallium sulfate (6× concentrated in low Cl− buffer) to each well and the transport kinetics were followed every 3 s for at least 120 s. To increase reading accuracy, a 10-ms delay was applied after each plate movement and one data point represents an average of 255 measurements. The relative transport rate was approximated as the rate of fluorescent intensity change per second based on the maximum initial rate which represents the best linear fit of 10 data points (i.e., 30 s) with highest slope. Student t test was used to evaluate the significance of NKCC1-mediated, bumetanide-sensitive transport activity.
Cryo-EM data acquisition
In all experiments, 3.5 μl of NKCC1 sample at ~3–5 mg/ml, supplemented with 50 µM furosemide, was applied to glow-discharged Au 1.2/1.3 holey, 300 mesh gold grids. Grids were plunge frozen in liquid ethane using a Vitrobot Mark III (FEI) set to 4 ˚C, 80% relative humidity, 20 s wait time, −1 mm offset, and 7 s blotting time. Data were collected on a Krios (FEI) operating at 300 kV equipped with the K2 Summit direct electron detector at the University of Utah, PNCC, NCCAT, and Yale University. Movies were recorded using SerialEM62, with a defocus range between −1.0 and −3.5 μm. Specifically, movies were recorded in super-resolution counting mode at a magnification of 47,619x, which corresponds to a physical pixel size of 1.05 Å. The data were collected at a dose rate of 1.56 e−/Å2/frame with a total exposure of 36 frames, giving a total dose of 56 e−/Å2.
Image processing 3D reconstruction and model building
Movie frames were aligned, dose weighted, and then summed into a single micrograph using MotionCor263. CTF parameters for micrographs were determined using the program CTFFIND464. Approximately 2000 particles were manually boxed out in RELION to generate initial 2D averages, which were then used as template to automatically pick particles from all micrographs65. A total of 899,683 particles were extracted in RELION, and then imported into cryoSPARC for one round of 2D classification66. ‘Junk’ particles that were sorted into incoherent or poorly resolved classes were rejected from downstream analyses. The remaining 489,720 particles from well-resolved 2D classes were pooled, and were used to calculate a de novo model in cryoSPARC without imposing any symmetry. The initial model was further improved to ~8 Å by homogenous refinement in cryoSPARC with C2 symmetry imposed. Subsequently, two rounds of heterogenous 3D classification were performed in cryoSPARC without imposing any symmetry using the 8 Å map as initial model. After the second round 3D classification, a single class showing clear secondary structural features and best map connectivity was selected. The 107,589 particles in this class were subjected to non-uniform refinement in cryoSPARC and yielded a 3.8 Å map. At this point, the 107,589 particles were exported into RELION for 3D classification without alignment (i.e., the Euler angles and in plane translations calculated by non-uniform refinement in cryoSPARC were maintained). The best class contains 75,748 particles which were again imported back to cryoSPARC for non-uniform refinement that calculated a final map of 3.46 Å resolution when solvent noise and detergent micelle belt were masked out.
The 3.46 Å resolution map was locally sharpened in cryoSPARC with an overall B factor of ~−100 Å2 for model building in Coot67. The model was refined in real space using PHENIX68, and assessed in Molprobity (Supplementary Table 2)69. We could not identify any densities to account for the furosemide molecule and future studies are needed to understand the site(s) and mechanism of inhibition by this clinically important class of loop diuretics. FSC curves were then calculated between the refined model vs summed half maps generated in cryosparc, and resolution was reported as FSC = 0.5 (Supplementary Fig. 2). The directional resolutions were calculated using a remote 3DFSC processing server (https://3dfsc.salk.edu/)70. UCSF Chimera was used to visualize and segment density maps, and figures were generated using Chimera and Pymol. HOLE program was used to calculate solvent accessible pathways45.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
The cyro-EM map of the human NKCC1 structure has been deposited in the Electron Microscopy Data Bank (EMDB) with the accession code EMD-20537. The atomic coordinate for the corresponding model has been deposited in the Protein Data Bank (PDB) with the accession code 6PZT. The source data underlying Fig. 6c, d and Supplementary Figs. 1B-E are provided as a Source Data file. All other data and reagents that support the findings of this study are available from the corresponding author upon reasonable request.
Markadieu, N. & Delpire, E. Physiology and pathophysiology of SLC12A1/2 transporters. Pflug. Arch. 466, 91–105 (2014).
Gamba, G. Molecular physiology and pathophysiology of electroneutral cation-chloride cotransporters. Physiol. Rev. 85, 423–493 (2005).
Russell, J. M. Sodium-potassium-chloride cotransport. Physiol. Rev. 80, 211–276 (2000).
Payne, J. A. Molecular operation of the cation chloride cotransporters: ion binding and inhibitor interaction. Curr. Top. Membr. 70, 215–237 (2012).
Lauf, P. K. et al. Erythrocyte K-Cl cotransport: properties and regulation. Am. J. Physiol. 263, C917–C932 (1992).
Delpire, E. & Gagnon, K. B. Na+-K+-2Cl− cotransporter (NKCC) physiological function in nonpolarized cells and transporting epithelia. Compr. Physiol. 8, 871–901 (2018).
Ben-Ari, Y. NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disorders. Trends Neurosci. 40, 536–554 (2017).
Delpire, E. & Staley, K. J. Novel determinants of the neuronal Cl(-) concentration. J. Physiol. 592, 4099–4114 (2014).
Dzhala, V. I. et al. NKCC1 transporter facilitates seizures in the developing brain. Nat. Med. 11, 1205–1213 (2005).
Blaesse, P., Airaksinen, M. S., Rivera, C. & Kaila, K. Cation-chloride cotransporters and neuronal function. Neuron 61, 820–838 (2009).
Kahle, K. T. et al. Roles of the cation-chloride cotransporters in neurological disease. Nat. Clin. Pr. Neurol. 4, 490–503 (2008).
Brumback, A. C. & Staley, K. J. Thermodynamic regulation of NKCC1-mediated Cl- cotransport underlies plasticity of GABA(A) signaling in neonatal neurons. J. Neurosci. 28, 1301–1312 (2008).
Simon, D. B. et al. Gitelman’s variant of Bartter’s syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na–Cl cotransporter. Nat. Genet. 12, 24–30 (1996).
Simon, D. B. et al. Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na–K–2Cl cotransporter NKCC2. Nat. Genet. 13, 183–188 (1996).
Ji, W. et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat. Genet. 40, 592–599 (2008).
Boyden, L. M. et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 482, 98–102 (2012).
Wilson, F. H. et al. Human hypertension caused by mutations in WNK kinases. Science 293, 1107–1112 (2001).
Kahle, K. T., Ring, A. M. & Lifton, R. P. Molecular physiology of the WNK kinases. Annu Rev. Physiol. 70, 329–355 (2008).
Malha, L. & Mann, S. J. Loop diuretics in the treatment of hypertension. Curr. Hypertens. Rep. 18, 27 (2016).
Sinha, A. D. & Agarwal, R. Thiazide diuretics in chronic kidney disease. Curr. Hypertens. Rep. 17, 13 (2015).
Bai, X., Moraes, T. F. & Reithmeier, R. A. F. Structural biology of solute carrier (SLC) membrane transport proteins. Mol. Membr. Biol. 34, 1–32 (2017).
Drew, D. & Boudker, O. Shared molecular mechanisms of membrane transporters. Annu Rev. Biochem. 85, 543–572 (2016).
Colas, C., Ung, P. M. & Schlessinger, A. SLC transporters: structure, function, and drug discovery. Medchemcomm 7, 1069–1081 (2016).
Monette, M. Y., Somasekharan, S. & Forbush, B. Molecular motions involved in Na-K-Cl cotransporter-mediated ion transport and transporter activation revealed by internal cross-linking between transmembrane domains 10 and 11/12. J. Biol. Chem. 289, 7569–7579 (2014).
Xu, J. C. et al. Molecular cloning and functional expression of the bumetanide-sensitive Na-K-Cl cotransporter. Proc. Natl Acad. Sci. USA 91, 2201–2205 (1994).
Moore-Hoon, M. L. & Turner, R. J. The structural unit of the secretory Na+-K+-2Cl− cotransporter (NKCC1) is a homodimer. Biochemistry 39, 3718–3724 (2000).
Parvin, M. N. & Turner, R. J. Identification of key residues involved in the dimerization of the secretory Na(+)-K(+)-2Cl(-) cotransporter NKCC1. Biochemistry 50, 9857–9864 (2011).
Simard, C. F. et al. Homooligomeric and heterooligomeric associations between K+-Cl- cotransporter isoforms and between K+-Cl- and Na+-K+-Cl- cotransporters. J. Biol. Chem. 282, 18083–18093 (2007).
Simard, C. F. et al. Self-interacting domains in the C terminus of a cation-Cl- cotransporter described for the first time. J. Biol. Chem. 279, 40769–40777 (2004).
Pedersen, M., Carmosino, M. & Forbush, B. Intramolecular and intermolecular fluorescence resonance energy transfer in fluorescent protein-tagged Na-K-Cl cotransporter (NKCC1): sensitivity to regulatory conformational change and cell volume. J. Biol. Chem. 283, 2663–2674 (2008).
Koumangoye, R., Omer, S. & Delpire, E. Mistargeting of a truncated Na-K-2Cl cotransporter in epithelial cells. Am. J. Physiol. Cell Physiol. 315, C258–C276 (2018).
Delpire, E. & Gagnon, K. B. SPAK and OSR1, key kinases involved in the regulation of chloride transport. Acta Physiol. 187, 103–113 (2006).
Dowd, B. F. & Forbush, B. PASK (proline-alanine-rich STE20-related kinase), a regulatory kinase of the Na-K-Cl cotransporter (NKCC1). J. Biol. Chem. 278, 27347–27353 (2003).
Piechotta, K., Lu, J. & Delpire, E. Cation chloride cotransporters interact with the stress-related kinases Ste20-related proline-alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1). J. Biol. Chem. 277, 50812–50819 (2002).
Monette, M. Y. & Forbush, B. Regulatory activation is accompanied by movement in the C terminus of the Na-K-Cl cotransporter (NKCC1). J. Biol. Chem. 287, 2210–2220 (2012).
Darman, R. B., Flemmer, A. & Forbush, B. Modulation of ion transport by direct targeting of protein phosphatase type 1 to the Na-K-Cl cotransporter. J. Biol. Chem. 276, 34359–34362 (2001).
Chew. T. A. et al. Structure and mechanism of the cation–chloride cotransporter NKCC1. Nature 572, 488–492 (2019).
Liu, S. et al. Cryo-EM structures of the human cation-chloride cotransporter KCC1. Science 366, 505–508 (2019).
Somasekharan, S., Monette, M. Y. & Forbush, B. Functional expression of human NKCC1 from a synthetic cassette-based cDNA: introduction of extracellular epitope tags and removal of cysteines. PLoS ONE 8, e82060 (2013).
Wang, L., Dong, C., Xi, Y. G. & Su, X. Thiazide-sensitive Na+-Cl- cotransporter: genetic polymorphisms and human diseases. Acta Biochim Biophys. Sin. (Shanghai) 47, 325–334 (2015).
Penmatsa, A. & Gouaux, E. How LeuT shapes our understanding of the mechanisms of sodium-coupled neurotransmitter transporters. J. Physiol. 592, 863–869 (2014).
Yamashita, A., Singh, S. K., Kawate, T., Jin, Y. & Gouaux, E. Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature 437, 215–223 (2005).
Krishnamurthy, H. & Gouaux, E. X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature 481, 469–474 (2012).
Vastermark, A. & Saier, M. H. Jr. Evolutionary relationship between 5+5 and 7+7 inverted repeat folds within the amino acid-polyamine-organocation superfamily. Proteins 82, 336–346 (2014).
Smart, O. S., Neduvelil, J. G., Wang, X., Wallace, B. A. & Sansom, M. S. HOLE: a program for the analysis of the pore dimensions of ion channel structural models. J. Mol. Graph 14, 354–360, 376 (1996).
Forrest, L. R., Tavoulari, S., Zhang, Y. W., Rudnick, G. & Honig, B. Identification of a chloride ion binding site in Na+/Cl-dependent transporters. Proc. Natl Acad. Sci. USA 104, 12761–12766 (2007).
Kantcheva, A. K. et al. Chloride binding site of neurotransmitter sodium symporters. Proc. Natl Acad. Sci. USA 110, 8489–8494 (2013).
Sun, M. et al. Genetic heterogeneity in patients with Bartter syndrome type 1. Mol. Med. Rep. 15, 581–590 (2017).
Somasekharan, S., Tanis, J. & Forbush, B. Loop diuretic and ion-binding residues revealed by scanning mutagenesis of transmembrane helix 3 (TM3) of Na-K-Cl cotransporter (NKCC1). J. Biol. Chem. 287, 17308–17317 (2012).
Carugo, O. Buried chloride stereochemistry in the Protein Data Bank. BMC Struct. Biol. 14, 19 (2014).
Aryal, P., Sansom, M. S. & Tucker, S. J. Hydrophobic gating in ion channels. J. Mol. Biol. 427, 121–130 (2015).
Payne, J. A. & Forbush, B. 3rd Alternatively spliced isoforms of the putative renal Na-K-Cl cotransporter are differentially distributed within the rabbit kidney. Proc. Natl Acad. Sci. USA 91, 4544–4548 (1994).
Igarashi, P., Vanden Heuvel, G. B., Payne, J. A. & Forbush, B. 3rd Cloning, embryonic expression, and alternative splicing of a murine kidney-specific Na-K-Cl cotransporter. Am. J. Physiol. 269, F405–F418 (1995).
Gimenez, I. & Forbush, B. The residues determining differences in ion affinities among the alternative splice variants F, A, and B of the mammalian renal Na-K-Cl cotransporter (NKCC2). J. Biol. Chem. 282, 6540–6547 (2007).
Gagnon, E., Bergeron, M. J., Daigle, N. D., Lefoll, M. H. & Isenring, P. Molecular mechanisms of cation transport by the renal Na+-K+-Cl- cotransporter: structural insight into the operating characteristics of the ion transport sites. J. Biol. Chem. 280, 32555–32563 (2005).
Doyle, D. A. et al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 280, 69–77 (1998).
Delpire, E. & Gagnon, K. B. Kinetics of hyperosmotically stimulated Na-K-2Cl cotransporter in Xenopus laevis oocytes. Am. J. Physiol. Cell Physiol. 301, C1074–C1085 (2011).
Gagnon, K. B. & Delpire, E. Molecular determinants of hyperosmotically activated NKCC1-mediated K+/K+ exchange. J. Physiol. 588, 3385–3396 (2010).
Lytle, C., McManus, T. J. & Haas, M. A model of Na-K-2Cl cotransport based on ordered ion binding and glide symmetry. Am. J. Physiol. 274, C299–C309 (1998).
Goehring, A. et al. Screening and large-scale expression of membrane proteins in mammalian cells for structural studies. Nat. Protoc. 9, 2574–2585 (2014).
Delpire, E. et al. Small-molecule screen identifies inhibitors of the neuronal K-Cl cotransporter KCC2. Proc. Natl Acad. Sci. USA 106, 5383–5388 (2009).
Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36–51 (2005).
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
Rohou, A. & Grigorieff, N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216–221 (2015).
Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519–530 (2012).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr 66, 486–501 (2010).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D. Biol. Crystallogr 66, 213–221 (2010).
Williams, C. J. et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 27, 293–315 (2018).
Tan, Y. Z. et al. Addressing preferred specimen orientation in single-particle cryo-EM through tilting. Nat. Methods 14, 793–796 (2017).
This work was primarily supported by the start-up fund from the University of Utah. E.C. is a Pew Scholar supported by the Pew Charitable Foundation. We thank the Utah Center for High Performance Computing for computational support, and David Timm and David Belnap for data collection at the Electron Microscope Core at the University of Utah. The Electron Microscope Core at the University of Utah was supported by a grant from the Beckman Foundation. A portion of this research was supported by NIH grant U24GM129547 and performed at the PNCC at OHSU and accessed through EMSL (grid.436923.9), a DOE Office of Science User Facility sponsored by the Office of Biological and Environmental Research. We thank Claudia Lopez, Harry Scott, and other staff members at the PNCC for data collection and technical support. Some of this work was performed at the National Center for CryoEM Access and Training (NCCAT) and the Simons Electron Microscopy Center located at the New York Structural Biology Center, supported by the NIH Common Fund Transformative High Resolution Cryo-Electron Microscopy program (U24 GM129539) and by grants from the Simons Foundation (SF349247) and NY State. We thank Ed Eng and Elina Kopylov at NCCAT for access to Krios microscopes and technical support. We thank Shenping Wu at the Yale University for access to their Krios microscope. We thank Aylin Rodan at the University of Utah for helpful discussion.
The authors declare no competing interests.
Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yang, X., Wang, Q. & Cao, E. Structure of the human cation–chloride cotransporter NKCC1 determined by single-particle electron cryo-microscopy. Nat Commun 11, 1016 (2020). https://doi.org/10.1038/s41467-020-14790-3